NCT00377273已完成4 期
An Open-Label 18-Month Safety Study of Fluorouracil Cream 0.5% for the Treatment of Actinic Keratoses
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 250
- 试验地点
- 2
- 主要终点
- The reduction in Actinic Keratosis lesion counts on other body sites from pretreatment to post-treatment and AK clearance of other body site lesions for Treatment Cycle 1.
研究概览
简要总结
This study is being undertaken to: 1. assess the safety of fluorouracil cream for the treatment of actinic keratoses ("AKs") on other common skin surface areas (e.g., posterior scalp, ears, neck, lips, arms and hands); 2. collect additional post-treatment safety data on fluorouracil cream applied to the face (including anterior scalp, if applicable); 3. assess the incidence of recurrence of AKs on the face; and 4. assess the need for re-treatment with fluorouracil cream to the face.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •The following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to potential participation in the trial, or to replace the advice of a personal physician or health professional.
- •INCLUSION CRITERIA:
- •Patients must give written informed consent;
- •Patients must have at least 5 visible and/or palpable AKs on the posterior scalp, ears, neck, lips, arms and/or hands (across all other body sites) and an additional 5 visible and/or palpable AKs on the face (including anterior scalp, if applicable);
- •Female patients must be post-menopausal for at least one year, or have had a hysterectomy, or have had a tubal ligation, or use oral/systemic contraceptives, an intrauterine device (IUD) or Norplant starting at least 28 days prior to study entry and throughout the study. Female patients of childbearing potential must have a negative urine pregnancy test prior to the first application of test medication
- •Patients must be compliant and willing to return to the study site for designated follow-up visits.
排除标准
- •Pregnant or lactating females;
- •Patients with a current skin condition on the face, scalp, ears, neck, lips, arms and/or hands that could confound the study, including basal cell and squamous cell carcinomas;
- •Patients with a known allergy to any ingredients of the test drug formulations;
- •Patients with known dihydropyrimidine dehydrogenase (DPD) enzyme deficiency;
- •Patients whose activities involve excessive or prolonged exposure to sunlight;
- •Patients who use a tanning parlor;
- •Patients treated with other topical agents for the treatment of actinic keratosis in the designated treatment area within 5 months prior to the start of the study are prohibited;
- •Patients who have had liquid nitrogen treatment for AKs within 4 weeks prior to study start in the designated treatment area;
- •History of drug or alcohol abuse.
结局指标
主要结局
The reduction in Actinic Keratosis lesion counts on other body sites from pretreatment to post-treatment and AK clearance of other body site lesions for Treatment Cycle 1.
次要结局
- The reduction in Actinic Keratosis lesion counts of the face (including anterior scalp, if applicable) from pretreatment to post-treatment and AK clearance of facial lesions for each Treatment Cycle
- The recurrence of facial lesions at 12 and 18 months post initial treatment, and the need for re-treatment.
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
2 期
A Randomized, Open, Prospective Clinical Research of Fluorouracil Implant to Improve Surgical Gallbladder Cancer and Bile Duct CancerGallbladder CancerBile Duct CancerNCT01317069Simcere Pharmaceutical Co., Ltd100
Unknown
2 期
The Effect of Fluorouracil Implants Regional Chemotherapy During the Surgical Treatment for Early Stage Hepatocellular CarcinomaEarly Stage Hepatocellular CarcinomaNCT01055743Simcere Pharmaceutical Co., Ltd250
已完成
3 期
Study of Ruxolitinib Cream in Adolescents With Atopic DermatitisAtopic Dermatitis (AD)NCT05456529Incyte Corporation103
已完成
3 期
Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric PatientsIron OverloadNCT00529152ApoPharma100
招募中
2 期
Fenofibrate in Patients With Primary Biliary Cholangitis (PBC)Primary Biliary CholangitisNCT06365424Xijing Hospital of Digestive Diseases117